Dormant Vaccine Manufacturing site currently owned by an affiliate of Liminal BioSciences intended to bring new capabilities to Ocugens medicine portfolio of Canadian and U.S. companiesCOVAXIN (BBV152), if approved, to be the first product manufactured in new upgraded facilityNew facility includes ... |